Administration of antivirals, IL-6 inhibitors, monoclonal neutralizing antibodies and systemic corticosteroids in acute SARS-CoV-2 infection do not reduce the subsequent burden of Long-COVID symptoms

Abstract: Le Infezioni in Medicina, n. 4, 391-403, 2025 doi: 10.53854/liim-3304-4 ORIGINAL ARTICLES Administration of antivirals, IL-6 inhibitors, monoclonal neutralizing antibodies and systemic corticosteroids in acute SARS-CoV-2 infection do not reduce the subsequent burden of Long-COVID symptoms Marco Floridia1, Liliana Elena Weimer1, Aldo Lo Forte2, Paolo Palange3, Maria Rosa Ciardi3, Patrizia Rovere-Querini4, Piergiuseppe Agostoni5,6, Emanuela Barisione7, Silvia Zucco8, Paola Andreozzi9, Paolo Bonfanti10,11, Stefano Figliozzi12,13, Matteo Tosato14, Donato Lacedonia15, Kwelusukila Loso16, Paola Gnerre17, Maria Antonietta di Rosolini18, Domenico Maurizio Toraldo19, Giuseppe Pio Martino20, Guido Vagheggini21,22, Gianfranco Parati23,24, Graziano Onder14, and the ISS Long-COVID Study Group. National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy; Department of Multidimensional Medicine, Internal Medicine Unit, San Giovanni di Dio Hospital, Florence, Italy; 3 Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy; 4 IRCCS Ospedale S. Raffaele and Vita-Salute San Raffaele University, Milan, Italy; 5 Centro Cardiologico Monzino, IRCCS, Milan, Italy; 6 Department of Clinical Science and Community Medicine, University of Milan, Milan, Italy; 7 IRCCS Ospedale Policlinico San Martino, Genova, Italy; 8 Infectious Diseases Unit, Ospedale Amedeo di Savoia, Turin, Italy; 9 Predictive Medicine Unit, Department of Internal Medicine, Endocrine-Metabolic Sciences and Infectious Diseases, Azienda Ospedaliero Universitaria Policlinico Umberto I, Rome, Italy; 10 Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy; 11 University of Milano-Bicocca, School of Medicine and Surgery, Monza, Italy; 12 IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; 13 Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy.; 14 Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy; 15 Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy; 16 Infectious Diseases and Hepatology Unit, Manduria Hospital, Taranto, Italy; 17 Internal Medicine Department, ASL 2 Savonese, Savona, Italy; 18 UOC Malattie Infettive, ASP Ragusa, Ragusa, Italy; 19 Respiratory Care Unit, Rehabilitation Department, “V. Fazzi” Hospital, Azienda Sanitaria Locale, San Cesario, Lecce, Italy; 20 Internal Medicine Unit, Hospital Augusto Murri, Fermo, Italy; 21 Department of Internal Medicine and Medical Specialties, Respiratory Failure Pathway, Azienda USL Toscana Nordovest, Pisa, Italy; 22 Fondazione Volterra Ricerche ONLUS, Volterra (Pisa), Italy; 23 Department of Clinical Sciences and Community Medicine, University of Milan, Milan, Italy; 24 IRCCS Istituto Auxologico Italiano, Milan, Italy. 1 2 Article received 21 July 2025 and accepted 30 September 2025 Corresponding author Marco Floridia E-mail: marco.floridia@iss.it 391 392 M. Floridia, L.E. Weimer, A. Lo Forte, et al. SUMMARY Purpose: Some studies have suggested that therapeutic interventions able to mitigate the acute phase of COVID-19 can also reduce the risk of Long-COVID and its severity, but the issue is still controversial. Methods: We examined in a national cohort of patients followed in Long-COVID centers the risk of persistent symptoms according to administration in acute COVID-19 of four drug classes: antivirals, IL-6 inhibitors, monoclonal..